Skip to main content
    C

    CareDx Inc (CDNA)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $73.72
    -4.16 (-5.34%)

    Market Cap: $4.09B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    CareDx Inc (CDNA) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    CareDx (CDNA) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, CareDx reported EPS of $0.70, above the $0.07 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    76%(28/37)
    Avg Surprise
    +73.18%
    Streak
    4 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.37
    Range$0.30 - $0.43
    10 analysts
    Revenue Consensus
    $135.45M
    Range$109.47M - $143.07M
    10 analysts
    Reports Apr 26, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.31
    Range$0.24 - $0.37
    7 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.30+2.2%
    60d ago$0.27+13.6%
    30d ago$0.25+22.5%
    7d ago$0.30+1.7%
    Current$0.31
    Revenue Consensus
    $130.93M
    Range$127.80M - $133.68M
    8 analysts

    Next Report

    CDNA has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 208.3% above the $0.12 reported for the quarter ended Dec 31, 2025.

    CDNA Earnings Call

    The latest CDNA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 37 quarters below that had an estimate, CDNA beat 28 and missed 9. The widest gap in the table came in the quarter ended Sep 30, 2026, when EPS landed 900.00% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.70$0.07N/A+900.00%Beat+150.0%65 up, 0 downOct 29, 2026N/A
    Jun 30, 2026$0.37$0.06N/A+516.67%Beat+270.0%51 up, 0 downJul 30, 2026$263.90M
    Mar 31, 2026$0.34$0.13$0.11 - $0.15+161.54%Beat+240.0%50 up, 4 downApr 28, 2026$117.70M
    Dec 31, 2025$0.12-$0.01N/AN/AN/A-33.3%61 up, 0 downFeb 24, 2026$108.39M
    Sep 30, 2025$0.28$0.14$0.12 - $0.17+100.00%Beat+100.0%61 up, 3 downNov 4, 2025$100.06M
    Jun 30, 2025$0.10$0.12$0.10 - $0.14-16.67%Miss-60.0%51 up, 4 downAug 6, 2025$86.68M
    Mar 31, 2025$0.10$0.07$0.06 - $0.09+42.86%BeatN/A61 up, 3 downApr 30, 2025$84.69M
    Dec 31, 2024$0.18$0.15$0.07 - $0.18+22.03%BeatN/A42 up, 0 downFeb 26, 2025$86.58M
    Sep 30, 2024$0.14$0.01-$0.02 - $0.06N/AN/AN/A63 up, 0 downNov 4, 2024$82.88M
    Jun 30, 2024$0.25-$0.14-$0.21 - -$0.12+278.57%BeatN/A51 up, 0 downJul 31, 2024$92.27M
    Mar 31, 2024-$0.03-$0.21-$0.28 - -$0.17+85.71%BeatN/A50 up, 1 downMay 9, 2024$72.05M
    Dec 31, 2023-$0.17-$0.27-$0.29 - -$0.24+37.04%BeatN/A51 up, 0 downFeb 28, 2024$65.57M
    Sep 30, 2023-$0.18-$0.40-$0.48 - -$0.35+55.00%BeatN/A50 up, 1 downNov 8, 2023$67.19M
    Jun 30, 2023-$0.18-$0.31-$0.57 - -$0.07+41.94%BeatN/A50 up, 0 downAug 8, 2023$70.30M
    Mar 31, 2023-$0.11-$0.10-$0.21 - -$0.05-10.00%MissN/A50 up, 0 downMay 10, 2023$77.26M
    Dec 31, 2022-$0.07-$0.09-$0.13 - -$0.02+22.22%BeatN/A50 up, 0 downFeb 27, 2023$82.38M
    Sep 30, 2022-$0.06-$0.14-$0.19 - -$0.09+57.14%Beat-185.7%50 up, 1 downNov 3, 2022$79.36M
    Jun 30, 2022-$0.13-$0.11-$0.16 - -$0.07-18.18%Miss-218.2%51 up, 0 downAug 4, 2022$80.63M
    Mar 31, 2022-$0.13-$0.04-$0.09 - -$0.01-225.00%Miss-192.9%50 up, 0 downMay 5, 2022$79.42M
    Dec 31, 2021-$0.03$0.03-$0.03 - $0.08-200.00%Miss-137.5%40 up, 0 downFeb 24, 2022$79.22M
    Sep 30, 2021$0.07$0.02-$0.02 - $0.05+250.00%Beat-30.0%5N/AOct 28, 2021$75.59M
    Jun 30, 2021$0.11$0.06$0.04 - $0.06+83.33%Beat+175.0%5N/AJul 29, 2021$74.19M
    Mar 31, 2021$0.14$0.01-$0.05 - $0.04N/AN/AN/A4N/AMay 5, 2021$67.40M
    Dec 31, 2020$0.08$0.02-$0.09 - $0.09+300.00%Beat+100.0%4N/AFeb 24, 2021$47.08M
    Sep 30, 2020$0.10-$0.06-$0.09 - -$0.01+266.67%Beat+400.0%3N/AOct 29, 2020$106.74M
    Jun 30, 2020$0.04-$0.04-$0.09 - $0.03+200.00%BeatN/A4N/AAug 4, 2020N/A
    Mar 31, 2020-$0.14$0.03$0.01 - $0.05-566.67%Miss-380.0%4N/AApr 30, 2020$38.38M
    Dec 31, 2019$0.04$0.02-$0.02 - $0.04+100.00%Beat+300.0%4N/AFeb 27, 2020$35.82M
    Sep 30, 2019$0.02$0.01-$0.10 - $0.12+100.00%BeatN/A4N/AOct 31, 2019$33.81M
    Jun 30, 2019-$0.19-$0.10N/A-90.00%MissN/A4N/AAug 1, 2019$31.45M
    Mar 31, 2019$0.05-$0.04-$0.06 - $0.00+225.00%BeatN/A4N/AMay 8, 2019$25.98M
    Dec 31, 2018$0.01-$0.09N/A+111.11%BeatN/A4N/AMar 6, 2019$23.51M
    Sep 30, 2018-$0.01-$0.03N/A+66.67%BeatN/AN/AN/ANov 8, 2018$21.18M
    Jun 30, 2018-$0.04-$0.07-$0.09 - -$0.05+42.86%BeatN/A2N/AAug 9, 2018$17.82M
    Mar 31, 2018-$0.14-$0.13-$0.13 - -$0.13-7.69%MissN/A1N/AMay 10, 2018$14.05M
    Dec 31, 2017-$0.09-$0.13-$0.17 - -$0.11+30.77%BeatN/A3N/AMar 22, 2018$12.50M
    Sep 30, 2017-$0.15-$0.17N/A+11.76%BeatN/AN/AN/ANov 9, 2017$12.19M
    Jun 30, 2017-$0.17-$0.20N/A+15.00%BeatN/AN/AN/AAug 10, 2017$12.05M
    Mar 31, 2017-$0.13-$0.17N/A+23.53%BeatN/AN/AN/AApr 21, 2017$11.58M
    Dec 31, 2016-$0.73-$0.18N/A-305.56%MissN/AN/AN/AMar 23, 2017$10.86M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.60, up 11.1% from the year before. It was -$1.54 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.60+11.1%
    Dec 31, 2024$0.54N/A
    Dec 31, 2023-$0.64N/A
    Dec 31, 2022-$0.39-234.5%
    Dec 31, 2021$0.29+262.5%
    Dec 31, 2020$0.08N/A
    Dec 31, 2019-$0.08N/A
    Dec 31, 2018-$0.18N/A
    Dec 31, 2017-$0.54N/A
    Dec 31, 2016-$1.54N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,700 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,66411
    2026Q2Jun 30, 20265,4588
    2026Q1Mar 31, 20267,55012
    2025Q4Dec 31, 20259,11313
    2025Q3Sep 30, 20256,92113
    2025Q2Jun 30, 20254,3089
    2025Q1Mar 31, 20256,74410
    2024Q4Dec 31, 20245,83411

    2026Q3 Earnings Call

    Opening remarks

    Nina Deka Head of Investor Relations Thank you, operator. Good afternoon. Thank you for joining us today. Earlier today, CareDx released financial results for the third quarter 2026, ending September 30, 2026. The results and our earnings presentation are available on the company's website at caredx.com. Joining me on today's call are John Hanna, President and Chief Executive Officer, and Keith Kennedy, Chief Operating Officer and Chief Financial Officer. Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements are based upon current estimates and various assumptions. These statements involve material risks and uncertainties that can cause actual results to differ materially from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. Information concerning the risks, uncertainties, and other factors that could cause results to differ from these forward-looking statements is included in our filings with the Securities and Exchange Commission. The information provided in this conference call speaks only to the live broadcast today, October 29, 2026. We disclaim any intention or obligation, except as required by law, to update or revise any information, financial projections, or other forward-looking statements, whether because of new information, future events, or otherwise. This call will also include a discussion of certain non-GAAP financial measures. These non-GAAP financial measures should be considered in addition to, not as a substitute or in isolation from, GAAP measures. Reconciliations of our non-GAAP financial measures to the most directly comparable GAAP financial measures may be found in today's earnings release or investor presentation, which are posted on our website. With that, I will now turn the call over to John.

    John Hanna President and Chief Executive Officer Thank you, Nina. Good afternoon, everyone, and thank you all for joining us today. We had another strong quarter of solid execution, extending our leadership in transplantation, expanding into specialty oncology, and preparing for our entrance into cell therapy. As a reminder, our strategy is to focus on markets where we believe our core competencies give us the right to win: markets where patients face a high burden of disease and are managed by a concentrated group of subspecialty providers, where the high cost of treatment and disease management warrants repeat molecular testing, and where our solution-selling approach, including integrated testing, digital solutions, and pharmacy, can create a competitive advantage. In my conversations with clinicians across transplantation, oncology, and cell therapy over the past quarter, the feedback is consistent.

    Frequently Asked Questions About CDNA

    When is CareDx's next earnings date?

    CareDx's next earnings report is expected for Feb 22, 2027.

    Did CDNA beat earnings estimates last quarter?

    Yes. CareDx reported EPS of $0.70 for the quarter ended Sep 30, 2026, above the $0.07 estimate, a 900.00% surprise.

    What EPS do analysts expect from CDNA next quarter?

    The consensus EPS estimate for CareDx for the quarter ending Dec 31, 2026 is $0.37 from 10 analysts, with estimates from $0.30 to $0.43.

    How often does CDNA beat earnings estimates?

    CareDx beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +250.63%.